Alliancebernstein L.P. Has $141.37 Million Holdings in Glaukos Corporation $GKOS

Alliancebernstein L.P. lifted its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 38.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,733,474 shares of the medical instruments supplier’s stock after buying an additional 481,620 shares during the quarter. Alliancebernstein L.P. owned about 3.02% of Glaukos worth $141,365,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 158 shares during the last quarter. REAP Financial Group LLC bought a new stake in shares of Glaukos in the 3rd quarter valued at about $40,000. SBI Securities Co. Ltd. raised its position in shares of Glaukos by 42.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after acquiring an additional 362 shares during the period. Smartleaf Asset Management LLC boosted its stake in Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Glaukos by 4,970.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,724 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 1,690 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

NYSE GKOS opened at $98.94 on Tuesday. The firm’s 50 day moving average is $114.35 and its 200-day moving average is $101.31. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $5.75 billion, a PE ratio of -30.35 and a beta of 0.70. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $130.23.

Glaukos (NYSE:GKOS) last released its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The business had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. During the same period last year, the business posted ($0.40) EPS. The firm’s revenue for the quarter was up 35.6% on a year-over-year basis. Equities research analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Aimee S. Weisner sold 15,000 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the completion of the transaction, the director directly owned 18,806 shares of the company’s stock, valued at approximately $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. This represents a 54.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 320,000 shares of company stock worth $37,202,909. Insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. William Blair raised shares of Glaukos to a “strong-buy” rating in a report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. The Goldman Sachs Group reiterated a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and issued a $131.00 price target on shares of Glaukos in a research note on Wednesday, February 18th. Finally, Needham & Company LLC increased their price objective on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.